Nanodelivery of cGAS-STING activators for tumor immunotherapy

Activation of the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway has great poten-tial to promote antitumor immunity. Development of activators for the cGAS-STING pathway (cGAS-STING activators) has profoundly revolutionized tumor immuno-therapy. However, successful clinical application of cGAS-STING activators is con-tingent on having appropriate systems to achieve safe, effective, and specific delivery. There is an increasing emphasis on the design and application of nano drug delivery systems (NDDS) that can facilitate the delivery potential of cGAS-STING activators. In this review, we discuss barriers for translational development of cGAS-STING activators (DNA damaging drugs and STING agonists) and recent advances of NDDS for these agents in tumor immunotherapy.

Automated summary

This article discusses the potential of cGAS-STING pathway activators in tumor immunotherapy, as well as the importance of nanodrug delivery systems in overcoming delivery barriers for these activators.